GERON CORP
GERN · Pharmaceutical Preparations · 641.5M shares · +28%/yr ↑ shares · EDGAR filings ↗
Reference price $1.94 · est. market cap ~$1.2B — last insider sale, 2026-02-18 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D50Commercial-launch biotech (Rytelo) narrowing losses but still cash-burning, funded.
Strengths
- Adequate liquidity — current ratio 4.7 (56th)
- Marketed product (Rytelo) ramping — per 10-K
Risks
- Still loss-making — ROE -37%, ROA -15%
- Launch-execution and single-product dependence — per 10-K
- Leverage — D/E 0.5 (67th)
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-37.0%
Return on assets
-14.6%
ROIC
-15.7%
Revenue growth (QoQ)
9.8%
Debt / equity
0.5×
Current ratio
4.7×
EBITDA
-$68M
Tangible book value
$226M
Cash & investments
$78M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | Spiegel Robert J. | Grant | 5.2K | $1.49 |
| 2026-02-18 | ROBERTSON MICHELLE | Option exercise | 28K | — |
| 2026-02-18 | ROBERTSON MICHELLE | Sell | 9.9K | $1.94 |
| 2025-12-31 | Spiegel Robert J. | Grant | 5.9K | $1.32 |
| 2025-09-30 | Spiegel Robert J. | Grant | 5.7K | $1.37 |
| 2025-06-30 | Spiegel Robert J. | Grant | 5.5K | $1.41 |
| 2025-05-09 | LAWLIS V BRYAN | Buy | 13K | $1.18 |
| 2025-03-31 | Spiegel Robert J. | Grant | 4.9K | $1.59 |
| 2025-02-27 | Samuels Scott Alan | Buy | 15K | $1.61 |
| 2025-02-27 | SCARLETT JOHN A | Buy | 12K | $1.76 |
| 2025-02-27 | Ziegler James | Buy | 100K | $1.60 |
| 2024-12-31 | Spiegel Robert J. | Grant | 2.2K | $3.54 |
| 2024-12-31 | Spiegel Robert J. | Grant | 2.2K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-27 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-03-26 | Exec/director change | filing ↗ |
| 2026-02-25 | ResultsExhibits | filing ↗ |
| 2026-01-12 | Reg FDExhibits | filing ↗ |
| 2026-01-06 | Material agreement | filing ↗ |
| 2025-12-16 | 2.05 | filing ↗ |
| 2025-11-05 | ResultsExhibits | filing ↗ |
| 2025-10-14 | Exec/director changeReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-27 | 2026-05-20 | 0001193125-26-241842 ↗ |
| 10-Q | 2026-05-06 | 2026-03-31 | 0000886744-26-000032 ↗ |
| 8-K | 2026-03-26 | 2026-03-25 | 0001193125-26-125151 ↗ |
| 10-K | 2026-03-02 | 2025-12-31 | 0000886744-26-000008 ↗ |
| 8-K | 2026-02-25 | 2026-02-25 | 0001193125-26-068523 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0000886744-26-000003 ↗ |
| 8-K | 2026-01-06 | 2026-01-05 | 0001193125-26-003388 ↗ |
| 8-K | 2025-12-16 | 2025-12-10 | 0000886744-25-000074 ↗ |
| 10-Q | 2025-11-07 | 2025-09-30 | 0000886744-25-000071 ↗ |
| 8-K | 2025-11-05 | 2025-11-05 | 0000886744-25-000068 ↗ |
| 8-K | 2025-10-14 | 2025-10-10 | 0001628280-25-044862 ↗ |
| 10-Q | 2025-08-06 | 2025-06-30 | 0000886744-25-000052 ↗ |